{"nctId":"NCT05276804","briefTitle":"The POUR (Postoperative Urinary Retention) Study","startDateStruct":{"date":"2022-04-13","type":"ACTUAL"},"conditions":["Postoperative Urinary Retention"],"count":171,"armGroups":[{"label":"Sugammadex","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex"]},{"label":"Retrospective cohort","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Sugammadex","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Over the age of 18\n* Undergoing laparoscopic inguinal hernia repair at Carolinas Medical Center by attending surgeons within the Division of Gastrointestinal and Minimally Invasive Surgery\n* Unilateral or bilateral inguinal hernia repair; may have concurrent umbilical hernia repair performed\n* Agreeable to participation in the study\n\nExclusion Criteria:\n\n* Patients who are having concurrent ventral or flank hernias repaired at time of operation or are having an inguinal hernia repair along with another operation (e.g.\n\nlaparoscopic cholecystectomy)\n\n* End-stage renal disease (Creatinine clearance less than 30)\n* Neuromuscular disease\n* Prior adverse reactions to Sugammadex\n* Patients who do not provide consent for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Urinary Retention","description":"Urinary retention is defined as the inability to void at six hours postoperatively, which will be recorded in the postoperative recovery area and the same definition for urinary retention will be applied to the comparative retrospective cohort","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Stay (Days)","description":"Patients will be followed from post surgery until discharge to determine the interim time","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.1"},{"groupId":"OG001","value":"0.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Hospital Cost","description":"Patient costs associated with procedure and hospital stay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57954","spread":"13448"},{"groupId":"OG001","value":"54970","spread":"19324"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Quality of Life Survey","description":"Quality of life survey given post hernia repair to evaluate mesh sensation, pain and movement limitations. 23 total items. Each item is scored 0 (no symptoms) to 5 (disabling symptoms). Total score range is 0-115 with a low score indicating surgery had no negative impact on quality of life.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Operation Time","description":"Number of minutes the operation lasted","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105.9","spread":"26.8"},{"groupId":"OG001","value":"102.1","spread":"51.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Morphine Milligram Equivalents","description":"Morphine milligram equivalents (MME) represents the potency of an opioid dose relative to morphine. MME is intended to help clinicians make safe, appropriate decisions concerning changes to opioid regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":"11.9"},{"groupId":"OG001","value":"38.0","spread":"17.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Clean Wounds at Follow Up","description":"Number of participants with clean wounds based on the Center for Disease Control and Prevention (CDC) Wound guidelines. CDC wound classification options are Clean, Clean-Contaminated, Contaminated, and Dirty/Infected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":[]}}}